Cooley advised Janux Therapeutics, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters related to the transaction, while Latham & Watkins advised the...
Janux Therapeutics’ $350 Million Common Stock Offering
Avidity Biosciences’ $300 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
Avidity Biosciences’ $461 Million Common Stock Offering
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
Matthey v. Johnson & Johnson et al.
King & Spalding secured a defense verdict for Johnson & Johnson in the cosmetic talcum powder litigation. In reaching its’ conclusion, the jury found that talc...
Boundless Bio’s $100 Million IPO
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Iovance Biotherapeutics’ US$211 Million Common Stock Offering
DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction. Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and...
Structure Therapeutics’ US$300 Million Private Placement Equity Financing
Latham & Watkins LLP represents Jefferies LLC and Leerink Partners LLC acting as placement agents in the financing. Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global...
HilleVax’s €100 Million Common Stock Public Offering
Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock
Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public...
Gossamer Bio’s $212 Million Private Placement Financing
Latham & Watkins represented Gossamer Bio in the transaction. Gossamer Bio, Inc. (Nasdaq: GOSS) announced that it has entered into a securities purchase agreement with institutional...
Janux Therapeutics’ $60 Million Offering of Common Stock and Pre-Funded Warrants
Cooley advised Janux, and Latham & Watkins advised the underwriter on the offering. Janux Therapeutics, Inc. (Nasdaq: JANX) has announced the pricing of an underwritten offering of...